Drug Trial Radar · NCT07869147
Study of ORJ-001 for the Treatment of IPF
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Oorja Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
ORJ-001Drug
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.
PlaceboOther
Matching placebo administered by subcutaneous injection twice weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)Time frame: From first dose through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood PressureTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body TemperatureTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart RateTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory RateTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen SaturationTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
- Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT IntervalTime frame: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
- Part B: Change from Baseline in Forced Vital Capacity (FVC)Time frame: Baseline to Week 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Innova Pharma Research, LLC
Doral, Florida · Recruiting
Clinical Research Associates of Central PA
DuBois, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.